September 20, 2022
Investors in biotechnology company Portola Pharmaceuticals Inc. have asked a San Francisco federal judge to give an initial nod to a $17.5 million deal that would end claims the company failed to acknowledge its prime drug candidate, a blood coagulant, would face stiff competition from an off-label drug used for the same purpose, hurting investors when the company revealed its struggles to sell its drug.
July 02, 2020
Portola Pharmaceuticals pushed a California federal judge to toss a proposed class action accusing the company of misstating the actual market value of its blood coagulant, Andexxa, arguing there is no evidence it misled its shareholders.
March 17, 2020
Glancy Prongay & Murray LLP on Monday sought to represent a proposed class of investors in a proposed securities fraud class action accusing biotechnology company Portola Pharmaceuticals Inc. of not properly explaining how changes related to its product reserves would affect its bottom line.